Therapeutics and diagnostic company focused on pandemic diseases.

Shuttle Pharmaceuticals develops radiation sensitizing drugs to improve the outcomes of patients undergoing radiation therapy for cancer treatment. Clinical phase drug candidates include ropidoxuridine for sensitizing rapidly growing tumors and doranidazole for sensitizing hypoxic cancers that are resistant to radiation therapy.

Seraxis, a private biotech company, is developing a cell therapy to cure insulin-dependent diabetes by replacing the beta cells of the pancreas. Their team of scientists created an induced Pluripotent Stem Cell (iPSC) line, that differentiates robustly into insulin-producing pancreatic cells. These cells are encapsulated to protect them from immune attacks and implanted in relevant models of type-1-diabetes. The safety and efficacy of the Seraxis therapy, SR-01, has been assessed in mice, rat and non-human primates in pre-clinical studies. The well-characterized and stable insulin-producing cells demonstrated a high level of purity, response to glucose challenge and secreted insulin over the 6 months of the studies. Additionally, Seraxis encapsulation technology was shown to efficiently protect these cells from the host immune destruction, while allowing vascularization and nutrition of the cells. In an on-going study, SR-01 has been shown to restore normal glycemic control in immune-competent diabetic rats for more than 3 months.

Neuralstem's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of central nervous system diseases and conditions.

Therapeutics for neurodegenerative diseases including for Parkinson's and Alzheimer's.

Developing innovation therapeutic monoclonal antibody drugs.

Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.

Building customized electronic health records for radiation oncology practices.

Business development for Health IT.

Intelligent Fusion Technology (IFT) specializes in the development and implementation of Data Fusion Technologies. IFT extracts the maximum amount of information from many data sources, to provide more accurate situational awareness than any individual data source could offer. IFT aggressively promotes the insertion of our revolutionary technologies into the marketplace by producing hardware and software for the Defense, Commercial, and Industrial sectors. Comprised of scientifically creative engineers with the rare ability to combine theoretical research and hardware implementation IFT develops products to for a wide range of complex needs.

HR consulting practice focused on healthcare professionals.

Developing a proprietary technology for isolating and using adult stem cells for treatment of osteoarthritis and rheumatoid arthritis

Akan Biosciences